How patients with metastatic prostate cancer can be informed by biomarker testing February 4, 2021 One out of every nine men—that’s how many will be diagnosed with prostate cancer in their lifetime. Most of those cases will be low risk—involving tumors that grow slowly and aren’t very aggressive. But in 10 to 20 percent of cases, within ~5 years of follow-up, the cancer develops into castration-resistant prostate cancer. This means that the tumors may not react to standard hormone therapy and, for at least 84 percent of patients, metastasize within five years of diagnosis, meaning the tumors spread to other areas like bones, organs, and lymph nodes.Read the full article here. Source: Alice Oglethorpe - Men's Health About Prostate Cancer Genetic Testing Prostate Cancer News Screening & PSA Test More for you
One out of every nine men—that’s how many will be diagnosed with prostate cancer in their lifetime. Most of those cases will be low risk—involving tumors that grow slowly and aren’t very aggressive. But in 10 to 20 percent of cases, within ~5 years of follow-up, the cancer develops into castration-resistant prostate cancer. This means that the tumors may not react to standard hormone therapy and, for at least 84 percent of patients, metastasize within five years of diagnosis, meaning the tumors spread to other areas like bones, organs, and lymph nodes.Read the full article here. Source: Alice Oglethorpe - Men's Health
